Site - Press Release Archive Press Release Archive 1998-2005 Keyword Search Year All20252024202320222021202020192018201720162015201420132012201120102009200820072006 May 18 2025 Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress May 16 2025 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 15 2025 Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology May 13 2025 Cytokinetics Announces Positive Topline Results From MAPLE-HCM May 08 2025 Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress May 07 2025 Cytokinetics to Hold Annual Meeting of Stockholders May 06 2025 Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update May 01 2025 Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy Apr 30 2025 Cytokinetics to Participate in May Investor Conferences Apr 22 2025 Cytokinetics to Announce First Quarter Results on May 6, 2025 Apr 17 2025 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 31 2025 Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference Mar 20 2025 Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community Mar 18 2025 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 17 2025 Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo Mar 03 2025 Cytokinetics to Participate in March Investor Conferences Feb 27 2025 Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update Feb 19 2025 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 13 2025 Cytokinetics to Announce Fourth Quarter Results on February 27, 2025 Feb 11 2025 Cytokinetics Names Robert E. Landry to Board of Directors Feb 05 2025 Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference Feb 04 2025 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 30 2025 Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program Jan 21 2025 Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction Jan 13 2025 Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 Jan 06 2025 Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference Jan 03 2025 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
